ANDA 78276, held by Rising Pharmaceuticals. Olmesartan Medoxomil.
As of Nov 21, 2026, ANDA 78276 (Olmesartan Medoxomil), held by Rising Pharmaceuticals, was first approved by FDA on Oct 26, 2016, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 26, 2016 | Original application | Approved |
| Olmesartan Medoxomil5MG · tablet;oral | Olmesartan Medoxomil | Discontinued |
| Olmesartan Medoxomil20MG · tablet;oral | Olmesartan Medoxomil | Discontinued |
| Olmesartan Medoxomil40MG · tablet;oral | Olmesartan Medoxomil | Discontinued |
| Sep 12, 2025 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 12, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 26, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters